Vaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
Vaxcyte has raised $632.5M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2026.
Vaxcyte's investors include RA Capital Management, Janus Henderson Investors, Abingworth, Foresite Capital, Frazier Healthcare Partners.
Vaxcyte is headquartered in San Carlos, United States.
Vaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
Vaxcyte is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vaxcyte — Funding & Investors." VCBacked, January 29, 2026, https://www.vcbacked.co/company/vaxcyte. Accessed July 19, 2026.
VCBacked. (2026). Vaxcyte — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/vaxcyte
{{cite web |title=Vaxcyte — Funding & Investors |url=https://www.vcbacked.co/company/vaxcyte |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated